Published in Acta Anaesthesiol Scand on August 01, 1992
Hypotension after spinal anesthesia for cesarean section: identification of risk factors using an anesthesia information management system. J Clin Monit Comput (2009) 0.87
Optimal Dose of Intrathecal Dexmedetomidine in Lower Abdominal Surgeries in Average Indian Adult. J Clin Diagn Res (2016) 0.80
Unanticipated cardiac arrest under spinal anesthesia: An unavoidable mystery with review of current literature. Anesth Essays Res (2015) 0.79
Multiple territory watershed infarcts following spinal anaesthesia. BMJ Case Rep (2014) 0.75
Prediction of hypotension in spinal anesthesia. Korean J Anesthesiol (2013) 0.75
A retrospective study to correlate breech presentation and enhanced risk of postspinal hypotension during cesarean delivery. Local Reg Anesth (2015) 0.75
The effects of spinal anaesthesia for elective caesarean section on uterine and umbilical arterial pulsatility indexes in normotensive and chronic hypertensive pregnant women: a prospective, longitudinal study. BMC Pregnancy Childbirth (2014) 0.75
Optimal dose of hyperbaric bupivacaine 0.5% for unilateral spinal anesthesia during diagnostic knee arthroscopy. Local Reg Anesth (2010) 0.75
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer (1994) 5.52
Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer (1998) 4.22
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol (2005) 4.00
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A (2001) 3.31
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol (1996) 2.83
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A (1998) 2.80
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
A digital atlas of breast histopathology: an application of web based virtual microscopy. J Clin Pathol (2004) 2.40
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer (2000) 2.24
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol (1992) 2.10
Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol (2000) 2.07
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol (2000) 2.01
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res (1996) 1.89
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer (1999) 1.82
Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol (2006) 1.68
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol (2007) 1.64
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res (2001) 1.60
Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.59
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol (1999) 1.42
Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res (1995) 1.38
Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst (1992) 1.36
Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer (1997) 1.34
Effect of age on the survival of breast cancer patients. Eur J Cancer (1997) 1.30
Virtual microscopy. J Clin Pathol (2004) 1.24
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol (2002) 1.22
Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol (1996) 1.17
MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res (2000) 1.16
Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer (2001) 1.15
Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol (1996) 1.13
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol (1998) 1.13
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet (1999) 1.12
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol (1997) 1.10
Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Genes Chromosomes Cancer (1999) 1.07
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol (2001) 1.07
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol (2007) 1.06
Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. Neuroendocrinology (1992) 1.03
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology (2005) 1.03
Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol (2000) 1.02
Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry (1991) 1.02
Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol (1994) 1.02
Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer (1994) 1.01
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer (2000) 1.01
Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer (1995) 0.99
Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol (1997) 0.98
Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol (1993) 0.98
Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy. Br J Cancer (1995) 0.98
Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res (2001) 0.95
HER2 oncogene amplification in extramammary Paget's disease. Histopathology (2003) 0.95
Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol (2006) 0.94
Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol (1992) 0.94
Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer (2000) 0.93
Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol (1994) 0.93
Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization. Cancer Res (1996) 0.92
A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals. J Clin Pathol (2007) 0.92
A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J Clin Pathol (2008) 0.91
Gluten affects epithelial differentiation-associated genes in small intestinal mucosa of coeliac patients. Clin Exp Immunol (2007) 0.91
Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control (2010) 0.91
Analysis of p53 tumor suppressor gene in families with multiple glioma patients. J Neurooncol (2001) 0.90
The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography. Breast Cancer Res Treat (2001) 0.89
New prognostic factors in prostatic carcinoma. Eur Urol (1993) 0.89
Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol (1995) 0.89
Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas. Am J Pathol (1997) 0.88
Mechanical loading regulates tenascin-C expression in the osteotendinous junction. J Cell Sci (1999) 0.88
The visibility of cancer on earlier mammograms in a population-based screening programme. Eur J Cancer (1999) 0.88
Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol (2011) 0.87
5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines. Genes Chromosomes Cancer (2001) 0.85
Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology (2002) 0.85
High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol (2000) 0.83
Localization of the glucocorticoid receptor in testis and accessory sexual organs of male rat. Mol Cell Endocrinol (1993) 0.82
Immunocytochemical localization of progesterone receptor in the chick ovary. Endocrinology (1987) 0.81
Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet (1997) 0.81
Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma. Br J Cancer (1990) 0.81
Direct eye visualization of Cy5 fluorescence for immunocytochemistry and in situ hybridization. J Histochem Cytochem (2000) 0.81
Incidence of atherosclerosis in the internal mammary artery. Ann Thorac Surg (1989) 0.81
Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Anticancer Res (2002) 0.81
c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer (1996) 0.81
Genetic aberrations in pediatric acute lymphoblastic leukemia by comparative genomic hybridization. Cancer Genet Cytogenet (1997) 0.81
Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas. J Clin Pathol (2005) 0.80
Colocalization of fos- and glucocorticoid receptor-like immunoreactivities in the rat amygdaloid complex after immobilization stress. J Neuroendocrinol (1992) 0.80
P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol (1997) 0.80
Immunochemical characterization of a novel mitochondrially located protein encoded by a nuclear gene within the DFNB8/10 critical region on 21q22.3. Biochem Biophys Res Commun (1997) 0.80
Development of progestin-specific response in the chicken oviduct. Int J Dev Biol (1989) 0.80
Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomized study. Br J Cancer (1998) 0.80
The visibility of cancer on previous mammograms in retrospective review. Clin Radiol (2001) 0.80
Prognostic variables in predicting pregnancy. A prospective follow up study of 907 couples with an infertility problem. Hum Reprod (1994) 0.79
Morphology and histochemistry of the myotendineal junction of the rat calf muscles. Histochemical, immunohistochemical and electron-microscopic study. Acta Anat (Basel) (1991) 0.79
Sources of variation in the assessment of cell proliferation using proliferating cell nuclear antigen immunohistochemistry. Anal Quant Cytol Histol (1994) 0.79
Progesterone receptor in the chick bursa of fabricius: characterization and immunohistochemical localization. Endocrinology (1985) 0.79
Evaluation of camera requirements for comparative genomic hybridization. Cytometry (1996) 0.78
Nuclear origin of progesterone receptor of the chick oviduct cytosol. An immunoelectron microscopic study. Histochemistry (1986) 0.77
High cell proliferation activity determined by DNA flow cytometry predicts poor prognosis after relapse in prostate cancer. Eur J Cancer (1994) 0.77
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neurooncol (1999) 0.77